Company Overview and News

 
NZ shares gain; Trade Me rises

2018-04-18 nzherald.co.nz
New Zealand shares gained in light trading as Fletcher Building's discounted rights issue and upcoming MSCI New Zealand index review weighed on investors' minds. Trade Me and Metlifecare increased while Comvita dropped.

1
The Interview: Kathmandu CEO Xavier Simonet finds a home in the outdoors

2018-04-13 nzherald.co.nz
Kathmandu's chief executive Xavier Simonet sees the public company as a New Zealand brand "born in the mountains".

 
'Have we just become slobs?': Video captures mess at Rebel Sport Botany during Easter sales

2018-04-03 nzherald.co.nz
A former journalist has shared a shocking video of the aftermath of Easter retail sales at a Rebel Sport store in Botany, Auckland.

 
'I'm old-fashioned': Myer's Hounsell goes shopping for people like him

2018-03-21 theage.com.au
So Myer’s newly minted executive chairman Garry Hounsell is following the very traditional path as he cleans up the mess created by the CEO he just fired: Richard Umbers.

 
'I'm old-fashioned': Myer's Hounsell goes shopping for people like him

2018-03-21 smh.com.au
So Myer’s newly minted executive chairman Garry Hounsell is following the very traditional path as he cleans up the mess created by the CEO he just fired: Richard Umbers.

 
Synlait Milk drives sharemarket to record high

2018-03-21 nzherald.co.nz
New Zealand's S&P/NZX 50 Index rose to a record led by Synlait Milk, which jumped to an all-time high after posting strong first-half earnings growth. Synlait's partner A2 Milk Co also gained, along with Kathmandu Holdings and the Fonterra Shareholders' Fund.

 
MARKET CLOSE: NZX 50 rises to record; Synlait jumps to all-time high

2018-03-21 nbr.co.nz
(BusinessDesk) - New Zealand's S&P/NZX 50 Index rose to a record led by Synlait Milk, which jumped to an all-time high after posting strong first-half earnings growth. Synlait's partner A2 Milk Co also gained, along with Kathmandu Holdings and the Fonterra Shareholders' Fund.

 
There's a successful Kiwi retailer on the ASX but no one's noticing

2018-03-15 theage.com.au
Would you believe we have a retailer on the ASX that has now reported eight consecutive years of record profits and it has reiterated its intent to acquire a rival retailer that is a household name.

 
There's a successful Kiwi retailer on the ASX but no one's noticing

2018-03-15 smh.com.au
Would you believe we have a retailer on the ASX that has now reported eight consecutive years of record profits and it has reiterated its intent to acquire a rival retailer that is a household name.

 
A2 Milk leads sharemarket higher

2018-03-12 nzherald.co.nz
New Zealand shares gained, led higher by A2 Milk Co on index inclusion speculation, with Pushpay and Kathmandu Holdings up.

 
MARKET CLOSE: NZ shares gain

2018-03-12 nbr.co.nz
(BusinessDesk) - New Zealand shares gained, led higher by A2 Milk Co on index inclusion speculation, with Pushpay and Kathmandu Holdings up.

 
Briscoe fends off margin squeeze as sales growth underpins profit gain

2018-03-12 nbr.co.nz
(BusinessDesk) - Briscoe Group [NZX:BGP] coped with a margin squeeze in the latest financial year to deliver a new record profit as sales growth continued to underpin earnings.

 
Briscoe Group posts new record full-year result - record sales, profitability eight years in a row

2018-03-12 nzherald.co.nz
Briscoe Group boss Rod Duke says he doesn't know why other retailers are performing so badly, as the company posts record profit - its eighth year in a row.

 
Work begins on Briscoes boss Rod Duke's James Bond-style Herne Bay helipad

2018-03-11 nzherald.co.nz
Briscoe Group managing director Rod Duke and his wife Patricia got resource consent in August to demolish an old boat shed near their property in Herne Bay and build a new one with a roof that folds back just as a chopper is about to land.

 
Stock Takes: Retail shake-up?

2018-02-22 nzherald.co.nz
This week's sale of outdoor brand Macpac to the Super Retail Group for $144 million could have implications for Kathmandu.

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...